

VODAFONE GROUP PUBLIC LTD CO

Form 8-A12B

March 16, 2006

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Vodafone Group Plc

(Exact Name of Registrant as Specified in Its Charter)

England and Wales	None
(State of Incorporation or Organization)	(I.R.S. Employer Identification No.)
Vodafone House, The Connection, Newbury, Berkshire, England	RG14 2FN
(Address of Principal Executive Office)	(Zip Code)

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

Securities Act registration statement file number to which this form relates: No. 333-110941.
Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of each exchange on which each class is to be registered
Floating Rate Notes due June 2011	The New York Stock Exchange
5.50% Notes due June 2011	The New York Stock Exchange
5.75% Notes due March 2016	The New York Stock Exchange

Securities to be registered pursuant to Section 12(g) of the Act:
None

(Title of Class)

INFORMATION REQUIRED IN REGISTRATION STATEMENT

The Registrant has filed with the Securities and Exchange Commission (the Commission) pursuant to Rule 424(b) under the Securities Act of 1933 a prospectus supplement, dated March 9, 2006 (the Prospectus Supplement), relating to its Floating Rate Notes due June 2011, its 5.50% Notes due June 2011 and its 5.75% Notes due March 2016 (collectively, the Registrant's Notes), which are to be registered hereunder, to a prospectus dated December 18, 2003 (the Prospectus) included in the Registrant's Amendment No. 1 to the Registration Statement on Form F-3 (File No. 333-110941) declared effective by the Commission on December 18, 2003. The Registrant has also filed a Form 6-K with the Commission on December 20, 2005, which contains an exhibit entitled Supplemental Description of Taxation (the Form 6-K). The Registrant incorporates by reference the Prospectus Supplement and the Prospectus and the Form 6-K to the extent set forth below.

Item 1. Description of Registrant's Securities to be Registered.

Reference is made to the information set forth under the headings Description of Notes in the Prospectus Supplement, under Description of Debt Securities We May Offer and Taxation in the Prospectus and under the heading Supplemental Description of Taxation in the Form 6-K, which information is incorporated herein by reference.

Item 2. Exhibits.

The Registrant's Notes are expected to be listed on the New York Stock Exchange (the NYSE), the exchange on which certain other securities of the Registrant are currently registered. Accordingly, copies of the following exhibits shall be filed with each copy of this Registration Statement filed with the Commission or with the NYSE, subject to Rule 12b-32 regarding the incorporation of exhibits by reference.

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, the following exhibits are being filed with the Commission in connection with this Registration Statement:

- 1.1 Indenture, dated as of February 10, 2000, between Vodafone Group Plc and Citibank, N.A., as Trustee, including forms of debt securities (incorporated by reference to Exhibit 4(a) filed in the Registrant's Post-Effective Amendment No.1 to its Registration Statement on Form F-3 (File No. 333-10762) filed with the Commission on November 24, 2000).

- 1.2 Officer's Certificate of the Registrant pursuant to Section 301 of the Indenture, dated March 16, 2006, setting forth the terms of its U.S.\$350,000,000 aggregate principal amount of Floating Rate Notes due June 2011, its U.S.\$750,000,000 aggregate principal amount of 5.50% Notes due June 2011 and its U.S.\$750,000,000 aggregate principal amount of 5.75% Notes due March 2016.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Vodafone Group Plc
(Registrant)

Date: March 16, 2006

By: /s/ Neil Garrod
Name: Neil Garrod
Title: Deputy Group Treasurer

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
1.1	Indenture, dated as of February 10, 2000, between Vodafone Group Plc and Citibank, N.A., as Trustee, including forms of debt securities (incorporated by reference to Exhibit 4(a) filed in the Registrant's Post-Effective Amendment No.1 to its Registration Statement on Form F-3 (File No. 333-10762) filed with the Commission on November 24, 2000).
1.2	Officer's Certificate of the Registrant pursuant to Section 301 of the Indenture, dated March 16, 2006, setting forth the terms of its U.S.\$350,000,000 aggregate principal amount of Floating Rate Notes due June 2011, its U.S.\$750,000,000 aggregate principal amount of 5.50% Notes due June 2011 and its U.S.\$750,000,000 aggregate principal amount of 5.75% Notes due March 2016.

ask4860830\25545-1-ba.htm',USER='105577',CD='Sep 5 15:31 2011' -->

analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; government, industry and general public pricing pressures; competition in general; the company's ability to obtain or maintain patent or other proprietary intellectual property protection, the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>.

References

- (1) **Novartis FDA Briefing Book, June 21, 2011.**

###

Novartis Media Relations

Central media line : +41 61 324 2200

Eric Althoff

Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com

Rute Frazao Marques

Novartis Global Pharma Communications
+41 61 696 8491 (direct)
+41 79 701 2009 (mobile)
rutfrazao.marques@novartis.com

e-mail: media.relations@novartis.com

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis

For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.

Novartis Investor Relations

Central phone:

Susanne Schaffert

Pierre-Michel Bringer

Thomas Hungerbuehler

Isabella Zinck

+41 61 324 7944

+41 61 324 7944

+41 61 324 1065

+41 61 324 8425

+41 61 324 7188

North America:

Richard Jarvis

Jill Pozarek

Edwin Valeriano

+1 212 830 2433

+1 212 830 2445

+1 212 830 2456

e-mail: investor.relations@novartis.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novartis AG

Date: **August 29, 2011**

By: /s/ MALCOLM B. CHEETHAM

Name: Malcolm B. Cheetham
Title: Head Group Financial
Reporting and Accounting